Aideen O'Neill
MBBS MRCP FRCPath
MRC- funded Clinical Research Training Fellow
I am a clinical haematologist and recently completed my DPhil, funded by an MRC Clinical Research Training Fellowship in the haematopoietic transplantation and immunotherapy group of Prof. Ronjon Chakraverty (second supervisor: Prof. Cristina lo Celso (Imperial College/ Francis Crick Institute)). Through my DPhil, I investigated a bone marrow stromal subset called leptin receptor + mesenchymal stromal cells (LepR+ MSCs), and their potential role in supporting anti-leukaemia T cells.
Prior to this, I completed my undergraduate degree in medicine at University College London. After qualifying I was awarded an NIHR Academic Foundation Post at UCL and an Academic Clinical Fellowship, also at UCL.
I am interested in the potential to target bone marrow stromal changes as a route to improving adoptively-transferred T cell and molecular anti-leukaemia therapies.
Recent publications
-
Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing
Arulogun SO. et al, (2023), American Journal of Hematology, 98, 750 - 759
-
Clinicoradiopathological correlation of symptomatic focal bone marrow lesions in Waldenström Macroglobulinaemia
Arulogun SO. et al, (2022), Leukemia & Lymphoma, 63, 1496 - 1499
-
Graft Versus Leukemia: Current Status and Future Perspectives.
O'Neill AT. and Chakraverty R., (2021), J Clin Oncol, 39, 361 - 372
-
The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single‐centre series
McMillan A. et al, (2021), British Journal of Haematology, 192
-
Focal, Symptomatic Bone Marrow Lesions in Waldenström Macroglobulinaemia Characterised By Dense Infiltration with Lymphoplasmacytic Lymphoma: A Newly Defined Indication for Systemic Treatment
Arulogun S. et al, (2020), Blood, 136, 3 - 4